Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.945 USD | +1.30% | -3.23% | -17.23% |
May. 09 | Transcript : Xeris Biopharma Holdings, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
May. 09 | Earnings Flash (XERS) XERIS BIOPHARMA HOLDINGS Reports Q1 Revenue $40.6M, vs. Street Est of $41.8M | MT |
Business Summary
Number of employees: 377
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Gvoke, Keveyis and Recorlev
93.6
%
| 109 | 99.1 % | 153 | 93.6 % | +40.36% |
Royalty, Contract and Other
6.4
%
| 1 | 0.9 % | 11 | 6.4 % | +971.07% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 110 | 100.0 % | 164 | 100.0 % | +48.68% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Paul Edick
CEO | Chief Executive Officer | 67 | 21-04-30 |
Steven Pieper
DFI | Director of Finance/CFO | 47 | 21-09-30 |
John Shannon
PSD | President | 62 | 21-10-04 |
Ken Johnson
CTO | Chief Tech/Sci/R&D Officer | 61 | 21-09-30 |
Allison Wey
IRC | Investor Relations Contact | - | - |
Kevin McCulloch
PRN | Corporate Officer/Principal | - | 18-09-30 |
Beth Hecht
LAW | General Counsel | 60 | 21-09-30 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
John Johnson
BRD | Director/Board Member | 66 | 21-10-04 |
Jeffrey Sherman
BRD | Director/Board Member | 69 | 21-10-04 |
Marla Persky
BRD | Director/Board Member | 68 | 21-10-04 |
Paul Edick
CEO | Chief Executive Officer | 67 | 21-04-30 |
Garheng Kong
BRD | Director/Board Member | 49 | 21-09-30 |
John Schmid
BRD | Director/Board Member | 61 | 21-10-04 |
Director/Board Member | 65 | 21-10-04 | |
Dawn Halkuff
BRD | Director/Board Member | 53 | 21-10-04 |
Ricki Fairley
BRD | Director/Board Member | 67 | 23-03-26 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 148,255,663 | 143,937,972 ( 97.09 %) | 0 | 97.09 % |
Company contact information
Xeris Biopharma Holdings, Inc.
1375 West Fulton Street Suite 1300
60607, Chicago
+
http://www.xerispharma.comSector
Sales per Business
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.23% | 285M | |
+39.08% | 727B | |
+30.57% | 592B | |
-7.88% | 347B | |
+15.55% | 319B | |
-0.31% | 274B | |
+12.55% | 238B | |
+6.65% | 204B | |
-6.09% | 203B | |
-3.23% | 160B |
- Stock Market
- Equities
- XERS Stock
- Company Xeris Biopharma Holdings, Inc.